4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta.

"Conflict of Interests None of the authors have any potential conflicts of interest to disclose."

"DK, DHC, and BHL are supported by NIH P01 HD070394. DK and DHC are also supported by NIH R01 AR066124. ID is supported by a Geisman Award from the Osteogenesis Imperfecta Foundation, Junta de Andalucia FEDER funds UMA18‐FEDERJA‐177, and the AHUCE foundation. PK was supported by Agency for Healthcare Research of the Czech Republic (Grant NV18‐08‐00567), and the Czech Science Foundation (Grants GA17‐09525S, GA19‐20123S). We appreciate the sharing of Aga2 mice by Dr. Martin Hrabé de Angelis to Dr. Christina M. Jacobson. Authors' roles: Conceptualization, ID, JZ, PK, and DK; Investigation, ID, JZ, FC, JHM, MB, DW, BD, BF, and CGA; Writing – Original Draft, ID, JZ, and DK; Writing – Review & Editing, DHC, PK, MLW, BHL, JZ, DW, and DK; Funding Acquisition, DK, DHC, and BHL; Resources, CMJ, PK, and MLW; Supervision, DK, DHC, and BHL."